DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

Leukemia

Volumn 26, Issue 5, 2012, Pages 1106-1107

  Metzeler, K H ^a   Walker, A ^a   Geyer, S ^a   Garzon, R ^a   Klisovic, R B ^a   Bloomfield, C D ^a   Blum, W ^a   Marcucci, G ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BORTEZOMIB; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; GENOMIC DNA; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BONE MARROW; CLINICAL ARTICLE; CLINICAL TRIAL; CODON; COHORT ANALYSIS; CYTOGENETICS; DNA METHYLATION; EXON; FEMALE; GENE DUPLICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CONSERVATION; HUMAN; KARYOTYPE; LETTER; LEUKOCYTE COUNT; MALE; METAPHASE; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION;

EID: 84860772157     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.342     Document Type: Letter

References (15)

1. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25: 1908-1915.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054.
3. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
4. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Nat Acad Sci USA 2010; 107: 7473-7478.
5. Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL et al. Array-based genomic resequencing of human leukemia. Oncogene 2010; 29: 3723-3731.
6. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433.
7. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43: 309-315.
8. Thol F, Damm F, Lü deking A, Winschel C, Wagner K, Morgan M et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011; 29: 2889-2896.
9. Becker H, Marcucci G, Maharry K, Radmacher MD, Mró zek K, Margeson D et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated geneand microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2009; 28: 596-604.
10. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mró zek K, Margeson D et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 2348-2355.
11. Metzeler KH, Maharry K, Radmacher MD, Mró zek K, Margeson D, Becker H et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011; 29: 1373-1381.
12. Dö hner H, Estey EH, Amadori S, Appelbaum FR, Bü chner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
13. Schwarz JM, Rö delsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010; 7: 575-576.
14. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 Function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
15. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-843.